Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

GSK to pocket $890 mln by halving stake in S.African drugmaker

March 14, 2015
Life sciences
(Reuters) – GlaxoSmithKline has decided to take profits in Aspen Pharmacare by halving its stake in the South African drugmaker, following a long investment in the firm.
 
The sale will be conducted through a share placing at a discount to the market price, which is expected to raise around $890 million.
 
Britain’s biggest drugmaker said on Thursday it would remain a 6.2 percent shareholder in Aspen and it had undertaken not to sell any more shares in the South African group for 180 days.
 
A source familiar with the matter said a price range of 365 to 385 rand per share had been set for the placement, representing a discount of 5.3 to 10.2 percent to Aspen’s closing price on Thursday.
 
The share sale is being run by Citi and UBS.
 
Simon Dingemans, GSK’s chief financial officer, said the disposal would help give his company flexibility to invest in new opportunities in the wake of a $20 billion-plus asset swap transaction with Novartis.
 
“As we continue to reshape the group around our core franchises and drive the benefits from the Novartis transaction, optimising our financial flexibility to invest behind these priorities is key,” he said in a statement.
 
“As a result we have decided now is the right time to realise further value from this successful relationship. We continue to believe in the strategy of Aspen and we remain committed to working together in the future.”
 
GSK said that the net profit on the disposal would not be included in core operating profit and core earnings in 2015, and GSK would no longer account for Aspen as an associate. (Reporting by Freya Berry, Vikram Subhedar and Ben Hirschler; Editing by Pamela Barbaglia, Greg Mahlich)

comments closed

Related News

September 7, 2024

UAE MoHAP and Novo Nordisk partner for obesity management

Life sciences

The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.

Read more
September 7, 2024

Lilly partners with Haya for lncRNA obesity target deal worth $1bn

Life sciences

Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.

Read more
September 7, 2024

Ashland completes sale of nutraceuticals business

Life sciences

The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.

Read more
More news